23
total announcements
CORONA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
P/E (TTM)
61.8
P/E (Forward)
38.3
EPS (TTM)
₹32.55
52W Low
₹1,336.60
52W High
₹2,292.40
Dividend Yield
0.50%
Price / Book
16.5
Debt / Equity
22.1
Revenue (TTM)
₹1,479 Cr
Gross Margin
80.82%
Operating Margin
18.91%
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about the schedule of its Analyst/Investor Call for Q2 FY27 earnings conference call on November 02, 2026 at 11:30 a.m. (IST) to discuss the financial results of the Company for the second quarter and half year ended on September 30, 2026.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, stating that Regulation 74(5) is not applicable to the Company as the entire holding of the Company's shares are in demat form.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about Credit Rating. CARE Ratings Limited has reaffirmed and revised the rating on the company's bank facilities.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about a scheduled meeting with analysts and investors on September 23, 2026, in Ahmedabad. The meeting will be organized by JP Morgan Group and will discuss publicly available information. No unpublished price-sensitive information will be discussed.
CORONA Remedies Limited
CORONA Remedies Limited has submitted a response to the National Stock Exchange of India Limited regarding a significant increase in volume, stating that the company is in compliance with listing obligations and has made all necessary disclosures.
CORONA Remedies Limited
CORONA Remedies Limited has seen a significant increase in trading volume, prompting the NSE to reach out to the company for clarification.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about its participation in an Analyst/Investor Conference on August 26, 2026, in Ahmedabad. The company officials will attend the conference to discuss publicly available information, and no unpublished price-sensitive information will be discussed.
CORONA Remedies Limited
CORONA Remedies Limited reported a 21.9% year-on-year revenue growth in Q1 FY27, surpassing its stated growth guidance of 15%. The company's India business delivered an impressive 22.7% year-on-year revenue growth, significantly outperforming the Indian Pharmaceutical Market, which grew by 11.6% during the same period.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about its participation in Analyst/Investor Conferences on August 13 and 14, 2026, in Mumbai. The company officials will attend the conferences and discuss publicly available information. No unpublished price sensitive information (UPSI) will be discussed.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding 'Machine Readable Financial results for Q1 2026-27'. The company has approved the unaudited standalone and consolidated financial results along with limited review reports for the first quarter and three months ended June 30, 2026.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about the link of recording for the Q1 FY27 earnings conference call, available on the company's website.
CORONA Remedies Limited
CORONA Remedies Limited has published unaudited financial results for the first quarter and three months ended on June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
CORONA Remedies Limited
CORONA Remedies Limited has released an investor presentation for Q1 FY27, highlighting its operational and financial performance, including revenue growth, improved rankings, and EU-GMP certification for its facilities.
CORONA Remedies Limited
CORONA Remedies Limited has announced its unaudited financial results for Q1FY27, reporting a revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y, driven by robust brand building and operational excellence.
CORONA Remedies Limited
CORONA Remedies Limited has submitted its financial results for Q1FY27, showing a revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y. The company has also announced the inauguration of its EU-GMP approved Female Hormone Manufacturing Facility and the integration of the Wokadine brand.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about the schedule of its Q1 FY27 earnings conference call to discuss the financial results for the first quarter and three months ended June 30, 2026.
CORONA Remedies Limited
CORONA Remedies Limited has submitted the Exchange a copy Scrutinizer report of Annual General Meeting held on July 09, 2026, and informed the Exchange regarding voting results.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 09, 2026, where the company passed various resolutions including final dividend declaration, auditor appointment, and director re-appointment.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the first quarter ended June 30, 2026.